PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it was selected by Chiesi Global Rare Diseases, a business unit of …
PITTSBURGH – PANTHERx Rare, the six-time winner of the Annual MMIT Patient Choice Award, once again, has the TOP Net Promoter Score for all independent specialty pharmacies in America for …
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it has been selected by UCB as a …
PITTSBURGH, June 21, 2023 /PRNewswire/ — PANTHERx Rare, the nation’s leading rare disease pharmacy, is excited to announce significant leadership changes as part of its ongoing growth and strategic development. …
Blueprint Medicines recently announced the approval of AYVAKIT® (avapritinib) for the expanded indication of adults with Indolent Systemic Mastocytosis (ISM). AYVAKIT was previously approved for the treatment of adults with …
Read the Official PANTHERx Press Release. PANTHERx Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy distribution partner for DIACOMIT® (stiripentol). DIACOMIT is a …
As a five-time MMIT Patient Choice Award Winner with a portfolio of 25+ rare programs, PANTHERx attributes much of our success to our ability to hire and cultivate talent while …
PANTHERx Rare Pharmacy is proud to have again earned the #1 ranking in the quarterly patient satisfaction survey conducted by MMIT, an independent national survey entity. For the first quarter of …
Read the Official PANTHERx Press Release. For a fifth time, PANTHERx Rare has been recognized as the winner of the annual, Specialty Pharmacy Patient Choice Award™. Since 2016, the Managed …
Change has been a constant in the specialty pharmacy industry since its inception over two decades ago. New medications are routinely launched, more patient populations receive treatment, and public awareness …
